Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

JOHNSON & JOHNSON

(JNJ)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Johnson & Johnson : Statement on U.S. FDA Approval of Shelf Life Extension for Company's COVID-19 Vaccine

07/28/2021 | 09:17pm EDT

NEW BRUNSWICK, N.J., July 29, 2021 -- We are pleased to confirm the U.S. Food & Drug Administration (FDA) has extended the shelf life for the Johnson & Johnson single-shot COVID-19 vaccine to six months. The decision is based on data from ongoing stability assessment studies, which have demonstrated the vaccine is stable at six months when refrigerated at temperatures of 36 - 46 degrees Fahrenheit (2 - 8 degrees Celsius). Expiration dates will be updated on www.vaxcheck.jnj, where vaccine providers can confirm the latest expiration dates of our vaccine.

Evidence has demonstrated that Johnson & Johnson's single-shot COVID-19 vaccine offers protection against COVID-19 disease and prevents hospitalization and death, including in countries where viral variants are highly prevalent. A single-shot vaccine that provides this level of protection represents an important tool in the global fight against COVID-19, as we strive to help end this deadly pandemic.

We continue to work with the U.S. government and health authorities to support the use of our vaccine, including among those who wish to be fully vaccinated with one shot.

Cautions Concerning Forward-Looking Statements

This statement contains 'forward-looking statements' as defined in the Private Securities Litigation Reform Act of 1995 regarding development of a potential preventive vaccine for COVID-19. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of the Janssen Pharmaceutical Companies, and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended January 3, 2021, including in the sections captioned 'Cautionary Note Regarding Forward-Looking Statements' and 'Item 1A. Risk Factors,' and in the company's most recently filed Quarterly Report on Form 10-Q, and the company's subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. None of the Janssen Pharmaceutical Companies nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.

###

Disclaimer

Johnson & Johnson published this content on 28 July 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 29 July 2021 01:16:05 UTC.


© Publicnow 2021
All news about JOHNSON & JOHNSON
12:21pJOHNSON & JOHNSON : Chris Rock says he has COVID-19, urges vaccination
AQ
11:52aJOHNSON & JOHNSON : RYBREVANT® (amivantamab-vmjw) Provides Higher Activity and L..
PU
11:52aJOHNSON & JOHNSON : New Data on RYBREVANT® (amivantamab-vmjw) in Combination wit..
PU
09/18MODERNA : U.S. administers about 384.9 mln doses of COVID-19 vaccines -CDC
RE
09/17Moderna Drops Ahead of FDA Committee COVID-19 Booster Decision
MT
09/17CDC DATA : Moderna vaccine has edge in preventing COVID-19 hospitalizations
AQ
09/17JOHNSON & JOHNSON : Slovenia starts mandatory vaccination for government workers
AQ
09/17JOHNSON & JOHNSON : Janssen Presents Results from Phase 1b/2 NORSE Study in Pati..
PU
09/17JOHNSON & JOHNSON : GSA Director Lauded for Luring More People to Get Covid-19 V..
AQ
09/17JOHNSON & JOHNSON : Unit Janssen's Schizophrenia Drug Gets European Medicines Ag..
MT
More news
Analyst Recommendations on JOHNSON & JOHNSON
More recommendations
Financials (USD)
Sales 2021 94 407 M - -
Net income 2021 22 809 M - -
Net Debt 2021 1 880 M - -
P/E ratio 2021 19,1x
Yield 2021 2,53%
Capitalization 434 B 434 B -
EV / Sales 2021 4,61x
EV / Sales 2022 4,42x
Nbr of Employees 134 500
Free-Float 84,3%
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 18
Last Close Price 164,75 $
Average target price 185,83 $
Spread / Average Target 12,8%
EPS Revisions
Managers and Directors
Alex Gorsky Chairman & Chief Executive Officer
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Paulus Stoffels Chief Scientific Officer
James D. Swanson Global Chief Information Officer & Executive VP
Charles O. Prince Independent Director
Sector and Competitors
1st jan.Capi. (M$)
JOHNSON & JOHNSON4.68%433 701
ROCHE HOLDING AG10.97%321 442
PFIZER, INC.20.81%246 078
NOVO NORDISK A/S50.80%232 556
ELI LILLY AND COMPANY36.28%208 604
ABBVIE INC.0.54%190 378